Treatment options for people diagnosed or living with small cell lung cancer (SCLC) are constantly improving and expanding. In fact, there are more drugs in development right now than were developed in total over the last 50 years. Investments [...]
On October 11, 2023, the American Society of Clinical Oncology (ASCO) recommended an update to its treatment guidelines for small cell lung cancer (SCLC). Cosela (trilaciclib) has been recommended as a myeloid supportive agent for individuals with extensive-stage SCLC who [...]
Small cell lung cancer (SCLC), which represents about 15% of all lung cancer diagnoses, is an often-aggressive form of lung cancer that has historically been difficult to treat. However, the science driving new treatments for SCLC is moving faster than [...]
Author: Jennifer C. King, PhD, Chief Scientific Officer People diagnosed with small cell lung cancer (SCLC) have historically had limited treatment options—but researchers are working to change that. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, [...]
Author: Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer The World Conference on Lung Cancer features research on all types of thoracic cancers—and small cell lung cancer is no exception. There were many talks on new [...]